Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing PEDMARK, a sodium thiosulfate formulation aimed at preventing platinum-induced ototoxicity. Key strengths include a high gross margin of 96% and strong liquidity ratios, indicating solid financial health and minimal debt. However, the low return on equity (4.6%) and modest EBITDA margin (9.7%) raise concerns about profitability and operational efficiency. The high gross margin juxtaposed with low valuation metrics suggests potential market skepticism regarding future growth prospects.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Exceptional revenue growth of 77.8% YoY demonstrates strong market demand and competitive positioning.
Operating margin expanded by 26.4pp, demonstrating strong operational leverage.
Both gross margin (+3.8pp) and operating margin (+26.4pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 93.7% indicates strong pricing power and competitive moat.
Gross margin improvement of 3.8pp suggests operational efficiency gains.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q2 (June 30, 2026)